The name of the game is more selective S1PR agonists with improved safety profile compared to the 1st gen - Gilenya and I think so far they are all hitting bumps and the S1P system is not sufficiently understood.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.